SynthesisSurgery today2025
Incidence of primary graft dysfunction and its associated risk factors after lung transplantation: a systematic review and meta-analysis.
Synthesis in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung transplantation in 2025: a narrative review of progress, challenges, and the road ahead.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This meta-analysis evaluates the prevalence of primary graft dysfunction (PGD) and its risk factors after lung transplantation (LT). We searched databases (PubMed, EMBASE, Cochrane Library, Web of Science) up until May, 2024. STATA 16 was used for data analysis. Random or fixed effects models were used to summarize the prevalence of PGD and associated risk factors according to statistical tests for heterogeneity. Risk of bias was assessed with the Newcastle-Ottawa Scale. A total of 61 studies with 59,865 patients were included. The pooled prevalence of grade 2 and grade 3 PGD was 27% (95% CI 0.19, 0.34) and 18% (0.16, 0.21), respectively. Donor-related risk factors included older age (OR = 1.04; 95% CI 1.00, 1.58), female gender (OR = 1.67; 95% CI 1.13, 2.48), and smoking history (OR = 1.84; 1.47, 2.30). Recipient factors were female gender (OR = 1.51; 95% CI 1.32, 1.74), higher BMI (OR = 1.22; 95% CI 1.11, 1.33), idiopathic pulmonary fibrosis (OR = 2.08; 95% CI 1.64, 2.63), and pulmonary hypertension (OR = 2.19; 95% CI 1.50, 3.21). Operative risks included higher reperfusion FiO
Indexed as
Identifiers
40960530What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.